All OPDP/DDMAC enforcement letters (since 1997) on the FDA website
Google search of FDA website for OPDP/DDMAC letters with the word "misleading" — replace "misleading" in the search box to search other terms
CY 2013 OPDP Enforcement Summaries
Covington & Burlington E-Alerts (monthly and end-of-year summaries of FDA promotional letters, including OPDP)
- 2012 End-of-Year Summary of FDA Promotional Enforcement Activity
- 2011 End-of-Year Summary of FDA Promotional Enforcement Activity
OPDP holds semi-annual webinars on recent enforcement letters (usually announced on its main webpage).
"Warning and Untitled Letters By Therapeutic Category – Oncology" by Mark Senak, Eye on FDA (June 2014)
"Use of Testimonials and Endorsements in Prescription Drug Advertisements" by Mary Sullivan, Regulatory Focus (September 2013)
"Patient Testimonial Videos: FDA Actions on Risk Information Presentation" by Dale Cooke, Regulatory Focus (July 2013)
"FDA Regulation of Pharma Communications in a Digital Era" White paper by Mark Senak, Eye on FDA (April 2013).
"Increased FDA Scrutiny Of Pre-Approval Communications Continued in 2012" Sidley Austin Update (February 2013)
"Changes in FDA enforcement activities following changes in federal administration: the case of regulatory letters released to pharmaceutical companies" BMC Health Serv Res. 2013 Jan 22;13:27
"Review of DDMAC / OPDP Warning and Untitled Letters By Therapeutic Category [2009-2011]" Sidley Austin Update (November 2011)